Business
Notice of Results
Notice of Results.
About this update from Physiomics Plc
[{"type":"text","content":"\n \n \n \n 9 September 2022\n \n \n \n \n \n \n Physiomics plc\n \n \n (\"Physiomics\") or (\"the Company\")\n \n \n \n \n \n \n \n \n Notice of Results\n \n \n \n \n \n \n \n \n \n \n \n Physiomics plc (AIM: PYC), the\n oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it will publish its results for the full year ending 30 June 2022 on Thursday, 29 September 2022.\n \n \n \n \n \n \n \n \n Enquiries:\n \n \n \n \n \n \n Physiomics plc \n \n \n \n Dr Jim Millen, CEO\n \n \n +44 (0)1865 784 980\n \n \n \n \n \n \n \n \n Hybridan LLP (broker)\n \n \n \n Claire Louise Noyce\n \n \n +44 (0) 203 764 2341\n \n \n \n \n \n \n Strand Hanson Ltd (NOMAD)\n \n \n \n James Dance & James Bellman\n \n \n +44 (0)20 7409 3494\n \n \n \n \n \n \n \n \n \n \n \n \n \n Notes to Editor\n \n \n \n \n \n \n \n About Physiomics\n \n \n \n \n \n \n Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.\n \n \n \n \n \n \n \n ","length":4215,"tagName":"div"}]